Document:

Exhibit 10.6

Exhibit 10.6

Directors Compensation

Effective January 1, 2009, compensation for each non-employee director of the Company is as
follows:

	 	(i)	 	$20,000 in cash;

	 	(ii)	 	7,500 shares of restricted stock issued under our 2006 Health Grades Inc. Equity
Compensation Plan, with 50% vesting on each of the first two anniversaries of the date
of grant; and

	 	(iii)	 	1,000 shares of restricted stock issued under our 2006 Health Grades Inc. Equity
Compensation Plan for serving as the Audit Committee Chairperson, with 50% vesting on
each of the first two anniversaries of the date of grant.exv10w1

 

Exhibit 10.1

SUPPLEMENT TO

TRANSACTION AGREEMENTS

          This Supplement to Transaction Agreements (this “Supplement”) is entered into as of
March 15, 2010 by and among Invus, L.P., a Bermuda limited partnership (“Invus, L.P.”),
Invus C.V., a Netherlands limited partnership (“Invus C.V.”, and, together with Invus,
L.P., the “Investors”), and Lexicon Pharmaceuticals, Inc., a Delaware corporation (the
“Company”). Capitalized terms used but not otherwise defined herein shall have the
meanings ascribed to them in the Securities Purchase Agreement (as defined below).

WITNESSETH:

          WHEREAS, Invus, L.P. and the Company entered into the Securities Purchase Agreement, dated as
of June 17, 2007, by and between Invus, L.P. and the Company (as amended, supplemented or otherwise
modified, the “Securities Purchase Agreement”), the Stockholders’ Agreement, dated as of
June 17, 2007 (as amended, supplemented or otherwise modified, the “Stockholders’
Agreement”) and the Registration Rights Agreement, dated as of June 17, 2007 (as amended,
supplemented or otherwise modified, the “Registration Rights Agreement”, and, together with
the Securities Purchase Agreement and the Stockholders’ Agreement, the “Transaction
Agreements”);

          WHEREAS, the Company desires to issue and sell shares of Company Common Stock in an
underwritten offering registered under the Securities Act (the “Offering”), which Offering
requires the consent of Invus, L.P. under the Securities Purchase Agreement; and

          WHEREAS, in connection with the Offering, Invus, L.P. and the Company desire to amend the
Transaction Agreements in certain respects, and assign certain rights under the Transaction
Agreements to Invus C.V.

          NOW, THEREFORE, intending to be legally bound hereby, the parties hereto hereby agree as
follows:

	Section 1. 	 	Amendment to the Securities Purchase Agreement

     The first sentence of Section 3.01(a) of the Securities Purchase Agreement is hereby amended
and restated in its entirety to read as follows:

Subject to Section 3.03(e), for a period of fifteen (15) months following the First
Rights Offering Trigger Date, the Investor shall have the right, but not the
obligation, exercisable by a written notice (the “First Rights Offering
Notice”) to the Company in accordance with Section 10.02, to require the Company
to make a pro rata offering (the “First Rights Offering”) to all holders of
Company Common Stock (including the Investor and its affiliates) of non-transferable
subscription rights (the “First Rights”) entitling the holders thereof to
purchase shares of Company Common Stock, on the terms set forth herein, (i) in
an aggregate amount equal to the First Rights Offering Amount, and (ii) at a
price per share (the “First Rights Offering Price”) to be designated by the
Investor at

 

2

any time on or after delivery of the First Rights Offering Notice and before the
establishment of the record date for the distribution of the First Rights to the
Company’s stockholders (provided that the establishment of such record date shall
not be prior to the time the First Rights Offering Registration Statement shall have
been declared effective by the SEC) by written notice (the “First Rights
Offering Pricing Notice”) to the Company in accordance with Section 10.02;
provided that the First Rights Offering Price shall be any price (A) at or above the
lower of $4.50 (as adjusted for any stock splits, reverse splits, stock dividends,
combinations or similar transactions occurring after the date hereof and prior to
the First Rights Offering) and the average of the volume weighted average trading
prices of the Company Common Stock on the Nasdaq Stock Market for the ten (10) full
trading days immediately prior to the date of the First Rights Offering Pricing
Notice (the “First Rights Offering Market Price”) and (B) at or below the
higher of $4.50 (as adjusted for any stock splits, reverse splits, stock dividends,
combinations or similar transactions occurring after the date hereof and prior to
the First Rights Offering) and the First Rights Offering Market Price.

	Section 2. 	 	Amendment to the Registration Rights Agreement

     (a) The definition of “Holders” in Section 1.01 of the Registration Rights Agreement is hereby
amended and restated in its entirety to read as follows:

“Holders” means the Investor, Invus C.V., a Netherlands limited partnership,
any Assigned Transferee and any affiliate of the Investor that holds Stock.

     (b) The parties hereto hereby intend that the foregoing amendment will give Invus C.V. and any
other person satisfying such definition the rights of Holders under the Registration Rights
Agreement. Pursuant to Section 5.06 of the Registration Rights Agreement, Invus, L.P., as the
Holder (as defined in the Registration Rights Agreement) of a majority of the outstanding shares of
Registrable Securities (as defined in the Registration Rights Agreement), hereby consents to the
above amendment to Section 1.01 of the Registration Rights Agreement, and the Company expressly
acknowledges the receipt of such consent.

	Section 3. 	 	Consent to Further Amendments; Further Assurances

     The parties hereto hereby consent to such other amendments and changes to the Securities
Purchase Agreement and Ancillary Agreements as necessary to give effect to the intent of this
Supplement and shall execute and deliver or cause to be executed and delivered any additional
documents, certificates, consents, waivers and instruments and perform any additional acts that may
be reasonably necessary or appropriate to effectuate and perform the provisions of this Supplement
and those transactions contemplated herein.

	Section 4. 	 	Assignments; Further Agreements

     (a) In connection with the Offering, the Company acknowledges that Invus C.V. will purchase
29,021,739 shares of Company Common Stock. Upon such purchase, Invus C.V. shall

 

3

have the same rights and obligations as the Investor (as defined in the applicable agreement) under
the Securities Purchase Agreement and Stockholders’ Agreement.

     (b) The parties hereto hereby agree that none of the shares of Company Common Stock acquired
by the Investors, whether directly from the Company or from the underwriters in the Offering
(including any shares in excess of Invus, L.P.’s Pro Rata Number (as defined in the Stockholders’
Agreement) of the sum of (x) the shares to be offered in the Offering and (y) the shares to be
purchased by the Investors directly from the Company), shall be Restricted Shares (as defined in
the Stockholders’ Agreement (any such shares, the “Pro Rata Excess Shares”)), and all such
shares shall be deemed to be acquired by the Investors as contemplated by the second sentence of
Section 4.01(a) for purposes of determining the Investors’ Percentage Limit (as defined in the
Stockholders’ Agreement) under the Stockholders’ Agreement.

     (c) The maximum amount of the First Rights Offering Amount and Second Rights Offering Amount
shall each be reduced by the sum of the net proceeds to the Company of the sales of shares of
Company Common Stock (x) in the Offering and (y) directly to the Investors.

     (d) Invus, L.P. hereby represents and warrants to the Company that Invus C.V. is an affiliate
(as defined in the Stockholders’ Agreement) of Invus, L.P.

	Section 5. 	 	Consent to Waiver of Investor Election Period in Section 4.02(b) of the 
Stockholders’ Agreement

     (a) With respect to the Offering (including any related overallotment option), the Company and
Invus, L.P. hereby waive any applicability to the Offering of the notice provisions contained in
Section 4.02(b) of the Stockholders’ Agreement and agree that notice will be delivered as follows:
the Company shall deliver a Notice of Issuance specifying the price to public and number of shares
to be sold to public in the Offering on the date the underwriting agreement is expected to be
signed by the Company in connection with the Offering and, upon receipt of such notice by Invus,
L.P., the Investors (i) shall exercise their rights under Section 4.02 with respect to the Offering
by delivering notice of such exercise substantially concurrently with the signing by the Company of
the underwriting agreement with respect thereto, and (ii) shall retain the right to make an
election whether to exercise their rights under Section 4.02 with respect to any additional New
Securities issued upon the exercise by the underwriters of their overallotment option in connection
with such Offering by delivering notice of such exercise as promptly as practicable following the
Company’s notice to Invus, L.P. of the underwriters’ exercise of such option. For the avoidance of
doubt, with respect to the Offering, Invus, L.P. waives its right to deliver notice of its intent
to participate in the Offering ten (10) business days following receipt of the Notice of Issuance
related thereto.

     (b) Invus, L.P. and Invus C.V. expressly acknowledge and agree that the provisions of Section
4.02(b) of the Stockholders’ Agreement relating to the free transferability of shares to be
received in the Offering shall not affect their obligations under their “lock-up” agreements dated
March 8, 2010 with the underwriters, which restrict the transferability of New Securities to be
issued by the Company in connection with the Offering.

 

4

	Section 6. 	 	Effectiveness; Termination

     This Supplement shall become effective only upon delivery by Invus, L.P. to the Company,
pursuant to Section 6.02(a) of the Securities Purchase Agreement, of Invus, L.P.’s written consent
to the Offering substantially in the form of Exhibit A hereto (the “Offering Consent”).
Notwithstanding any such delivery, in the event that the underwriting agreement relating to the
Offering is not executed on or before March 26, 2010, (i) this Supplement shall terminate and cease
to have any force or effect and (ii) the Offering Consent shall be of no force or effect.

	Section 7. 	 	Ratification and Confirmation

     The Transaction Agreements, as hereby amended, supplemented or otherwise modified, are hereby
ratified and confirmed in all respects. This Supplement shall be interpreted and construed
together with, and as a part of, each of the Transaction Agreements, as applicable. Any reference
in any other document to any of the Transaction Agreements shall be deemed to refer to the
applicable Transaction Agreement, as modified by this Supplement. The execution, delivery and
effectiveness of this Supplement shall not constitute a modification or waiver of any provision of
the Transaction Agreements except as expressly provided herein.

	Section 8. 	 	Governing Law

     This Supplement shall be governed by, and construed in accordance with, the laws of the State
of New York. All actions and proceedings arising out of or relating to this Supplement shall be
heard and determined exclusively in any New York state or federal court, in each case sitting in
the Borough of Manhattan. The parties hereto hereby (a) submit to the exclusive jurisdiction of
any New York state or federal court, in each case sitting in the Borough of Manhattan, for the
purpose of any Action arising out of or relating to this Supplement brought by any party hereto,
and (b) irrevocably waive, and agree not to assert by way of motion, defense, or otherwise, in any
such Action, any claim that it is not subject personally to the jurisdiction of the above-named
courts, that its property is exempt or immune from attachment or execution, that the Action is
brought in an inconvenient forum, that the venue of the Action is improper, or that this Supplement
may not be enforced in or by any of the above-named courts.

	Section 9. 	 	Counterparts

     This Supplement may be executed and delivered (including by facsimile transmission) in one or
more counterparts, and by the different parties hereto in separate counterparts, each of which when
executed and delivered shall be deemed to be an original but all of which taken together shall
constitute one and the same agreement.

[Signature Page Follows]

 

 

          IN WITNESS WHEREOF, the Investors and the Company have caused this Supplement to be
executed as of the date first written above by their respective officers thereunto duly authorized.

	 	 	 	 	 
	 	INVESTORS:

INVUS, L.P.,

a Bermuda limited partnership

 	 
	 	By:  	Invus Advisors, L.L.C., its general partner
 	 
	 	 	 
	 	By:  	                        /s/ Raymond Debbane
 	 
	 	 	Name:  	Raymond Debbane 	 
	 	 	Title:  	President 	 
	 

	 	 	 	 	 
	 	INVUS C.V.,

a Netherlands limited partnership

 	 
	 	By:  	Ulys, L.L.C., its general partner
 	 
	 	 	 
	 	By:  	                        /s/ Raymond Debbane
 	 
	 	 	Name:  	Raymond Debbane 	 
	 	 	Title:  	President 	 
	 

	 	 	 	 	 
	 	COMPANY:

LEXICON PHARMACEUTICALS, INC.,

a Delaware corporation

 	 
	 	By:  	/s/ Arthur T. Sands
 	 
	 	 	Name:  	Arthur T. Sands, M.D., Ph.D. 	 
	 	 	Title:  	President and Chief Executive Officer 	 
	 

[Signature Page to Supplement to Transaction Agreements]

 

 

Exhibit A

NOTICE OF

CONSENT TO OFFERING

March ___, 2010

Invus, L.P.

c/o The Invus Group, LLC

750 Lexington Avenue (30th Floor)

New York, New York 10022

Lexicon Pharmaceuticals, Inc.

8800 Technology Forest Place

The Woodlands, Texas 77381

Attn: President and Chief Executive Officer

Ladies and Gentlemen:

     Reference is made to that certain Securities Purchase Agreement, dated as of June 17, 2007 (as
amended, supplemented or otherwise modified, the “Securities Purchase Agreement”), by and
between Invus, L.P. and Lexicon Pharmaceuticals, Inc. (the “Company”), and to that certain
Supplement to Transaction Agreements, dated as of March 15, 2010, by and among Invus, L.P., Invus
C.V. and the Company. Capitalized terms used but not otherwise defined herein shall have the
meanings ascribed to them in the Securities Purchase Agreement.

     Pursuant to Section 6.02(a) of the Securities Purchase Agreement, Invus, L.P. hereby consents
to an underwritten offering by the Company of Company Common Stock on the following terms:

Issuer: Lexicon Pharmaceuticals, Inc.

Offering:                      shares of Company Common Stock (the “Firm Shares”) and up to
                     additional shares to cover over-allotments by the underwriters in such offering as
provided in the underwriting agreement to be executed in connection with such offering (the
“Underwriting Agreement”)

Size: $                     at a $                     per share purchase price to the public.

Timing: Pricing to occur on or before March 15, 2010 with closing within T+3
(subject to extension as provided in the Underwriting Agreement).

	 	 	 	 	 
	 	Sincerely,

INVUS, L.P.,

a Bermuda limited partnership

 	 
	 	By:  	Invus Advisors, L.L.C., its general partner
 	 
	 	 	 
	 	By:  	

 	 
	 	 	Name:  	 	 
	 	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]